Payment overview · 2025
General Payments
$152.70
9 reported records · 6 companies
Healthcare provider profile · identity verified
Wulf Hirschfield, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WAYNESBORO, MS · NPI 1114995537
Verified facts
What the public records show
CMS Open Payments records show Wulf Hirschfield, MD received $152.70 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.15 | 42.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.93 | 18.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.44 | 12.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.21 | 11.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.25 | 10.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $7.72 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.70 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $7.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 197 |
| Gabapentin | Gabapentin | 628 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 627 | 198 |
| Potassium Chloride | Potassium Chloride | 503 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 448 | 130 |
| Eliquis | Apixaban | 420 | 69 |
| Omeprazole | Omeprazole | 420 | 124 |
| Furosemide | Furosemide | 392 | 137 |
| Carvedilol | Carvedilol | 347 | 94 |
| Prednisone | Prednisone | 346 | 169 |
| Losartan Potassium | Losartan Potassium | 332 | 110 |
| Famotidine | Famotidine | 319 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 302 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 76 |
| Lisinopril | Lisinopril | 288 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 280 | 94 |
| Tramadol Hcl | Tramadol Hcl | 273 | 67 |
| Metformin Hcl Er | Metformin Hcl | 262 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 69 |
| Azithromycin | Azithromycin | 243 | 202 |
| Glimepiride | Glimepiride | 220 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 218 | 55 |
| Trazodone Hcl | Trazodone Hcl | 216 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 71 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 213 | 64 |
| Metformin Hcl | Metformin Hcl | 213 | 57 |
| Memantine Hcl | Memantine Hcl | 199 | 36 |
| Clonazepam | Clonazepam | 195 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 57 |
| Meloxicam | Meloxicam | 180 | 56 |
| Xarelto | Rivaroxaban | 177 | 27 |
| Jardiance | Empagliflozin | 173 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 43 |
| Simvastatin | Simvastatin | 163 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 145 | 88 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 39 |
| Spironolactone | Spironolactone | 141 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 135 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 38 |
| Allopurinol | Allopurinol | 130 | 39 |
| Donepezil Hcl | Donepezil Hcl | 130 | 27 |
| Sertraline Hcl | Sertraline Hcl | 121 | 34 |
| Pregabalin | Pregabalin | 115 | 23 |
| Levetiracetam | Levetiracetam | 114 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 113 | 22 |
| Farxiga | Dapagliflozin Propanediol | 113 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 109 | 29 |
| Entresto | Sacubitril/Valsartan | 108 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 13 |
| Ondansetron Odt | Ondansetron | 105 | 49 |
| Alprazolam | Alprazolam | 101 | 17 |
| Buspirone Hcl | Buspirone Hcl | 98 | 29 |
| Finasteride | Finasteride | 97 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 74 |
| Nystatin | Nystatin | 96 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 95 | 25 |
| Mirtazapine | Mirtazapine | 93 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 92 | 33 |
| Fluconazole | Fluconazole | 89 | 55 |
| Methocarbamol | Methocarbamol | 87 | 38 |
| Alendronate Sodium | Alendronate Sodium | 85 | 13 |
| Lactulose | Lactulose | 81 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 79 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 17 |
| Myrbetriq | Mirabegron | 78 | suppressed |
| Sucralfate | Sucralfate | 77 | 24 |
| Chlorthalidone | Chlorthalidone | 75 | 30 |
| Linzess | Linaclotide | 75 | 22 |
| Ozempic | Semaglutide | 75 | 15 |
| Risperidone | Risperidone | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 16 |
| Baclofen | Baclofen | 71 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 70 | 18 |
| Ertapenem | Ertapenem Sodium | 70 | 12 |
| Santyl | Collagenase Clostridium Hist. | 68 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 17 |
| Lovastatin | Lovastatin | 66 | 26 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 65 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 36 |
| Divalproex Sodium | Divalproex Sodium | 63 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 55 |
| Temazepam | Temazepam | 62 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 31 |
| Ibuprofen | Ibuprofen | 61 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 13 |
| Amoxicillin | Amoxicillin | 59 | 42 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 17 |
| Metolazone | Metolazone | 58 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 35 |
| Latanoprost | Latanoprost | 53 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 30 |
| Levofloxacin | Levofloxacin | 52 | 38 |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Valsartan | Valsartan | 51 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Fenofibrate | Fenofibrate | 50 | 16 |
| Glipizide | Glipizide | 48 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 24 |
| Colchicine | Colchicine | 46 | 21 |
| Diltiazem Hcl | Diltiazem Hcl | 46 | 14 |
| Lorazepam | Lorazepam | 46 | 14 |
| Nitroglycerin | Nitroglycerin | 46 | 30 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 25 |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | 14 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 15 |
| Atenolol | Atenolol | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 35 | 17 |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Promethazine Hcl | Promethazine Hcl | 34 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 20 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 30 | 20 |
| Calcitriol | Calcitriol | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Haloperidol | Haloperidol | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | 22 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 17 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 17 |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Haloperidol Lactate | Haloperidol Lactate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levofloxacin-D5w | Levofloxacin In Dextrose 5 % | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.70 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, FARXIGA, Kerendia, NUZYRA, Ozempic, QULIPTA, XHANCE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error